CN Patent

CN101535279B — 含锌结合基的喹唑啉基egfr抑制剂

Assigned to Curis Inc · Expires 2015-05-20 · 11y expired

What this patent protects

本发明化合物涉及含锌结合基的喹唑啉基衍生物及其在EGFR-TK相关疾病和紊乱如癌症治疗中的使用，含锌结合基的喹唑啉基衍生物作为表皮细胞生长因子受体酪氨酸激酶(EGFR-TK)具有增强的和预想不到的性质。上述衍生物可进一步起到HDAC抑制剂的作用。

USPTO Abstract

本发明化合物涉及含锌结合基的喹唑啉基衍生物及其在EGFR-TK相关疾病和紊乱如癌症治疗中的使用，含锌结合基的喹唑啉基衍生物作为表皮细胞生长因子受体酪氨酸激酶(EGFR-TK)具有增强的和预想不到的性质。上述衍生物可进一步起到HDAC抑制剂的作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN101535279B
Jurisdiction
CN
Classification
—
Expires
2015-05-20
Drug substance claim
No
Drug product claim
No
Assignee
Curis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.